Nymox Pharmaceutical Corp NT 20-F, filed Mar 31, 2023
Nymox Pharmaceutical Corp (NYMXF)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
| SEC FILE NUMBER 000-54332 | |
| CUSIP NUMBER |
| (Check one): | ☐ Form 10-K | ☒ Form 20-F | ☐ Form 11-K | ☐ Form 10-Q | ☐ Form 10-D |
|
| ☐ Form N-CEN | ☐ Form N-CSR |
|
|
|
|
| For Period Ended: December 31, 2022 | |
|
|
|
|
|
| ☐ | Transition Report on Form 10-K |
|
| ☐ | Transition Report on Form 20-F |
|
| ☐ | Transition Report on Form 11-K |
|
| ☐ | Transition Report on Form 10-Q |
|
|
|
|
|
| For the Transition Period Ended: ___________________________________ | |
| Read Instructions (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
| PART I -REGISTRANT INFORMATION |
|
|
| NYMOX PHARMACEUTICAL CORPORATION |
| Full Name of Registrant |
|
|
| N/A |
| Former Name if Applicable |
|
|
|
Bay & Deveaux Streets |
| Address of Principal Executive Office (Street and Number) |
|
|
|
Nassau, The Bahamas |
| City, State and Zip Code |
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
|
| (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
|
|
|
| ☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10- K, Form 20-F, ll-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
|
|
|
|
|
| (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
NYMOX PHARMACEUTICAL CORPORATION (the “Company”) has determined that it is unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “Form 20-F”) within the prescribed time period without unreasonable effort and expense. The Company is still in process of compiling certain required information to complete the Form 20-F. As a result, the Company requires additional time to prepare and review its consolidated financial statements and other disclosures in the Form 20-F. The Company expects to file the Form 20-F on or before the fifteenth calendar day extension provided by Rule 12b-25.
PART IV - OTHER INFORMATION
| (1) | Name and telephone number of person to contact in regard to this notification |
|
M. Richard Cutler |
| (713) |
| 888-0040 |
| (Name) |
| (Area Code) |
| (Telephone Number) |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No |
|
|
|
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No |
|
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |
|
| |
| Cautionary Note Regarding Forward-Looking Statements | |
|
| |
| This Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, the Company’s expectations as to the outcome of its review of its financial statements.
These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management’s current expectations include, among other things, the discovery of additional information relevant to the internal review; the conclusions of management (and the timing of the conclusions) concerning matters relating to the internal review; the timing of the review by, and the conclusions of, the Company’s independent registered public accounting firm regarding the internal review and the Company’s financial statements; the possibility that errors may be identified; and the risk that the completion and filing of the Form 20-F will take longer than expected. The Company disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. | |
| 2 |
NYMOX PHARMACEUTICAL CORPORATION
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 31, 2023 | By: | /s/ Paul Averback | |
|
| Name: | Paul Averback |
|
|
| Title: | President and Chief Executive Officer |
|
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
|
| ATTENTION |
|
| Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). | ||
| 3 |